NanoViricides Advances MPox Treatment Amid WHO Emergency Extension

NanoViricides, Inc., a company developing broad-spectrum antivirals, announced its progress on NV-387 for MPox treatment as WHO extends the public health emergency status. WHO's decision follows a rise in MPox cases, especially in Africa, posing a global threat. NV-387 aims to address this issue by advancing to Phase II clinical trials.

Unlike existing treatments, NV-387 uses host-mimetic nanomedicine technology, making it harder for viruses to evade. Tecovirimat and brincidofovir, current alternatives, have shown limited effectiveness and safety in treating MPox, accentuating the need for new solutions like NV-387.

While tecovirimat and brincidofovir were stockpiled for bioterrorism preparedness, their inadequacies in MPox highlight NV-387's potential. NanoViricides sees a successful trial paving the way to significant market opportunities.